Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Infections × Anidulafungin × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Neutropenia 1 Myelodysplastic Syndromes 1 Leukemia, Myeloid, Acute 1 Leukemia 1 Invasive Fungal Infections 1 Infections 1 Hematologic Neoplasms 1 Carcinoma, Hepatocellular 1 Candidiasis, Invasive 1

Interventions

Trimethoprim, Sulfamethoxazole Drug Combination 8 Ciprofloxacin 7 Voriconazole 4 Vancomycin 4 Fluconazole 3 Filgrastim 3 Daptomycin 3 Antibiotic Prophylaxis 3 Amoxicillin-Potassium Clavulanate Combination 3 plerixafor 2 gamma-Globulins 2 Trimethoprim 2 Therapeutics 2 Sulfamethoxazole 2 Saline Solution 2 Ribavirin 2 Polymerase Chain Reaction 2 Piperacillin, Tazobactam Drug Combination 2 Peripheral Blood Stem Cell Transplantation 2 Pentetic Acid 2 Moxifloxacin 2 Melphalan 2 Levofloxacin 2 Lenalidomide 2 Itraconazole 2 Immunoglobulins, Intravenous 2 Granulocyte Colony-Stimulating Factor 2 Fosfomycin 2 Ethanol 2 Cyclophosphamide 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00068471 2013-06-19

Anidulafungin in Treating Immunocompromised Children With Neutropenia

National Cancer Institute (NCI)

Phase 1/2 Completed

Infections, Neutropenia

Data powered by HemOnc (CC BY 4.0) Colophon ⚡